sabato, 8 febbraio 2025
Medinews
7 Gennaio 2019

EU Panel Backs Dasatinib for Pediatric Ph+ ALL

December 17, 2018 – The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has granted a positive opinion to dasatinib in combination with chemotherapy for the treatment of pediatric patients with newly diagnosed Philadelphia chromosome (Ph)-positive acute lymphoblastic leukemia (ALL), according to Bristol-Myers Squibb, the manufacturer of the TKI. This recommendation includes dasatinib in tablet form and powder for … (leggi tutto)

TORNA INDIETRO